neoadjuvant herceptin may rid axillary nodes of disease
 

now if we could find out which 72% get pCR (pathological complete responses) ahead of time we could avoid lymph node dissections of all types and perhaps get rid of lymphedema! This holds only for her2 positive patients obviously!

ABSTRACT: Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer
[Cancer]

Background: The axillary pathologic complete response rate (pCR) and the effect of axillary pCR on disease-free survival (DFS) was determined in patients with HER2-positive breast cancer and biopsy-proven axillary lymph node metastases who were receiving concurrent trastuzumab and neoadjuvant chemotherapy. The use of neoadjuvant chemotherapy is reported to result in pCR in the breast and axilla in up to 25% of patients. Patients achieving a pCR have improved DFS and overall survival. To the authors' knowledge, the rate of eradication of biopsy-proven axillary lymph node metastases with trastuzumab-containing neoadjuvant chemotherapy regimens has not been previously reported.

Methods: Records were reviewed of 109 consecutive patients with HER2-positive breast cancer and axillary metastases confirmed by ultrasound-guided fine-needle aspiration biopsy who received trastuzumab-containing neoadjuvant chemotherapy followed by breast surgery with complete axillary lymph node dissection. Survival was evaluated by the Kaplan-Meier method. Clinicopathologic factors and DFS were compared between patients with and without axillary pCR.

Results: Eighty-one patients (74%) achieved a pCR in the axilla. Axillary pCR was not associated with age, estrogen receptor status, grade, tumor size, initial N classification, or median number of lymph nodes removed. More patients with an axillary pCR also achieved a pCR in the breast (78% vs 25%; P < .001). At a median follow-up of 29.1 months, DFS was significantly greater in the axillary pCR group (P = .02).

Conclusions: Trastuzumab-containing neoadjuvant chemotherapy appears to be effective in eradicating axillary lymph node metastases in the majority of patients treated. Patients who achieve an axillary pCR are reported to have improved DFS. The success of pCR with concurrent trastuzumab and chemotherapy in eradicating lymph node metastases has implications for surgical management of the axilla in these patients.

Re: neoadjuvant herceptin may rid axillary nodes of disease
 

Lani,

I am so glad you posted this. I had mistakenly thought pCR was a partial response, not pathological complete response.

This sounds very promising to me. I wish I would have been given the option of neoadjuvant chemotherapy. It might have helped me avoid the axillary node dissection after finding 1 positive sentinal node.

Re: neoadjuvant herceptin may rid axillary nodes of disease
 

I had neoadjuvant chemo and herceptin, and it worked, but they took 17 lymph nodes out anyway, as I understand it was because it is so difficult to tell just by a scan (MRI) if the nodes really are negative or not, and we didn't want to take any chances. All nodes removed were found to be completely clear. Are there any advancements being made in scans or tests to determine if nodes are negative?

Re: neoadjuvant herceptin may rid axillary nodes of disease
 

Thank you for sharing. I came close to getting a Pcr with my lymph nodes; darn! Maybe Pcr in the breast helps DFS.
Kris....